Nitriles

• 

  Subject Areas on Research

  • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. 
  • A negative charge in transmembrane segment 1 of domain II of the cockroach sodium channel is critical for channel gating and action of pyrethroid insecticides. 
  • A new irreversibly inhibited form of xanthine oxidase from ethylisonitrile. 
  • A nuclear factor-kappaB inhibitor BAY11-7082 inhibits interactions between human endothelial cells, T cells, and monocytes. 
  • A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND). 
  • ALSUntangled 48: Perampanel (Fycompa). 
  • ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. 
  • Activation by odorants of a multistate cation channel from olfactory cilia. 
  • Activation of protein kinase C inhibits human keratinocyte migration. 
  • Alternative splicing of an insect sodium channel gene generates pharmacologically distinct sodium channels. 
  • An alanine in segment 3 of domain III (IIIS3) of the cockroach sodium channel contributes to the low pyrethroid sensitivity of an alternative splice variant. 
  • An examination of the proconvulsant actions of pyrethroid insecticides using pentylenetetrazol and amygdala kindling seizure models. 
  • An important role of a pyrethroid-sensing residue F1519 in the action of the N-alkylamide insecticide BTG 502 on the cockroach sodium channel. 
  • An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. 
  • Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy. 
  • Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. 
  • Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease. 
  • Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials. 
  • Batrachotoxin, pyrethroids, and BTG 502 share overlapping binding sites on insect sodium channels. 
  • Bi-directional migration of lens epithelial cells in a physiological electrical field. 
  • Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. 
  • Biochemical recurrence of prostate cancer. 
  • Blockade of the extracellular signal-regulated kinase pathway by U0126 attenuates neuronal damage following circulatory arrest. 
  • Cellular mechanisms of sex determination in the red-eared slider turtle, Trachemys scripta. 
  • Characterization of Isavuconazole serum concentrations after enteral feeding tube administration in a hospitalized cohort: A case series. 
  • Characterization of deltamethrin metabolism by rat plasma and liver microsomes. 
  • Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. 
  • Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. 
  • Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo. 
  • Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. 
  • Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. 
  • Co-regulation of nuclear respiratory factor-1 by NFkappaB and CREB links LPS-induced inflammation to mitochondrial biogenesis. 
  • Comparative field evaluation of combinations of long-lasting insecticide treated nets and indoor residual spraying, relative to either method alone, for malaria prevention in an area where the main vector is Anopheles arabiensis. 
  • Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. 
  • Copper-Catalyzed 1,2-Aminocyanation of Unactivated Alkenes via Cyano Migration. 
  • Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. 
  • Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist. 
  • Cyanogenic glycosides and menisdaurin from Guazuma ulmifolia, Ostrya virgininana, Tiquilia plicata and Tiquilia canescens. 
  • DHX15 is up-regulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations. 
  • Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. 
  • Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. 
  • Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. 
  • Developmental origin of peripheral ciliary band neurons in the sea urchin embryo. 
  • Differential effects of TipE and a TipE-homologous protein on modulation of gating properties of sodium channels from Drosophila melanogaster. 
  • Disruption of dystroglycan-laminin interactions modulates water uptake by astrocytes. 
  • Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations. 
  • Drug susceptibility and resistance mutations after first-line failure in resource limited settings. 
  • ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity. 
  • Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. 
  • Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. 
  • Effect of a fluvalinate-resistance-associated sodium channel mutation from varroa mites on cockroach sodium channel sensitivity to fluvalinate, a pyrethroid insecticide. 
  • Effects of dietary exposure to the pyrethroid pesticide esfenvalerate on medaka (Oryzias latipes). 
  • Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells. 
  • Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. 
  • Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses. 
  • Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. 
  • Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. 
  • Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. 
  • Electric fields and MAP kinase signaling can regulate early wound healing in lens epithelium. 
  • Enantioselective Intermolecular Pd-Catalyzed Hydroalkylation of Acyclic 1,3-Dienes with Activated Pronucleophiles. 
  • Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. 
  • Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. 
  • Enzalutamide in metastatic prostate cancer before chemotherapy. 
  • Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. 
  • Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. 
  • Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study. 
  • Erk/MAP kinase signaling pathway and neuroendocrine differentiation of non-small-cell lung cancer. 
  • Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. 
  • Estrogen protects against intracranial aneurysm rupture in ovariectomized mice. 
  • Estrogen receptor-β ligand treatment after disease onset is neuroprotective in the multiple sclerosis model. 
  • Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. 
  • Evaluating the extent of intramolecular charge transfer in the excited states of rhenium(I) donor-acceptor complexes with time-resolved vibrational spectroscopy. 
  • Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. 
  • Factor Xa induces tissue factor expression in endothelial cells by P44/42 MAPK and NF-κB-dependent pathways. 
  • Finally, a Successful Randomized Trial for GVHD. 
  • Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. 
  • Fine scale spatial investigation of multiple insecticide resistance and underlying target-site and metabolic mechanisms in Anopheles gambiae in central Côte d'Ivoire. 
  • Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. 
  • Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. 
  • Glutathione S-transferase-mediated chlorothalonil metabolism in liver and gill subcellular fractions of channel catfish. 
  • Human lung innate immune response to Bacillus anthracis spore infection. 
  • Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis. 
  • Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. 
  • Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. 
  • Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. 
  • Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. 
  • Increased survival with enzalutamide in prostate cancer after chemotherapy. 
  • Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer. 
  • Induction of Neuroinflammation and Neurotoxicity by Synthetic Hemozoin. 
  • Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. 
  • Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis. 
  • Interleukin-1beta elevates cyclooxygenase-2 protein level and enzyme activity via increasing its mRNA stability in human endometrial stromal cells: an effect mediated by extracellularly regulated kinases 1 and 2. 
  • Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. 
  • Isavuconazole for treatment of rare invasive fungal diseases. 
  • Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. 
  • Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. 
  • Janus kinase inhibitors for atopic dermatitis: a promising treatment modality. 
  • Joint acute toxicity of esfenvalerate and diazinon to larval fathead minnows (Pimephales promelas). 
  • Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). 
  • Kinetics of interaction of disopyramide with the cardiac sodium channel: fast dissociation from open channels at normal rest potentials. 
  • LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression. 
  • Leflunomide for polyomavirus type BK nephropathy. 
  • Letrozole in the treatment of breast cancer. 
  • Ligand-specific dynamics of the androgen receptor at its response element in living cells. 
  • Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. 
  • Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. 
  • Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape. 
  • Molecular basis of selective resistance of the bumblebee BiNa_v 1 sodium channel to tau-fluvalinate. 
  • Molecular determinants for enzalutamide-induced transcription in prostate cancer. 
  • Molecular determinants on the insect sodium channel for the specific action of type II pyrethroid insecticides. 
  • N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway. 
  • Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect. 
  • Novel sodium channel gene mutations in Blattella germanica reduce the sensitivity of expressed channels to deltamethrin. 
  • Ontogeny of hepatic and plasma metabolism of deltamethrin in vitro: role in age-dependent acute neurotoxicity. 
  • Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors. 
  • Organotypic models of type III interferon-mediated protection from Zika virus infections at the maternal-fetal interface. 
  • PET scanning in mild cognitive impairment. 
  • Pathogenesis of duodenal ulcer. Gastric hyperacidity caused by propionitrile and cysteamine in rats. 
  • Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. 
  • Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis. 
  • Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. 
  • Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. 
  • Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. 
  • Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. 
  • Primary brain tumours in Fischer 344 rats chronically exposed to acrylonitrile in their drinking-water. 
  • Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? 
  • Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. 
  • Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. 
  • Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. 
  • Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation. 
  • Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. 
  • Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. 
  • Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. 
  • Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. 
  • Regulation of the macrophage population in postnatal rat testis. 
  • Reply to M.A.N. Şendur et al and J. Michels. 
  • Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. 
  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. 
  • Role of mitogen-activated protein kinase in osteoblast differentiation. 
  • Roles of estrogen in the formation of intracranial aneurysms in ovariectomized female mice. 
  • Rotational Symmetry of Two Pyrethroid Receptor Sites in the Mosquito Sodium Channel. 
  • Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. 
  • Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study. 
  • Ruxolitinib: a new treatment for myelofibrosis. 
  • Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study. 
  • Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population. 
  • Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America. 
  • Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study. 
  • Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. 
  • Self-Assembling Peptide Gels for 3D Prostate Cancer Spheroid Culture. 
  • Simultaneous measurement of myocardial perfusion and ventricular function during exercise from a single injection of technetium-99m sestamibi in coronary artery disease. 
  • Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging. 
  • Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer. 
  • Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. 
  • Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics. 
  • Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. 
  • Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents. 
  • Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4. 
  • Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. 
  • Synergistic interaction between two cockroach sodium channel mutations and a tobacco budworm sodium channel mutation in reducing channel sensitivity to a pyrethroid insecticide. 
  • Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer. 
  • TRPV4 is necessary for trigeminal irritant pain and functions as a cellular formalin receptor. 
  • Testosterone with dutasteride, but not anastrazole, improves insulin sensitivity in young obese men: a randomized controlled trial. 
  • The Arabidopsis epithiospecifier protein promotes the hydrolysis of glucosinolates to nitriles and influences Trichoplusia ni herbivory. 
  • The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. 
  • The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML). 
  • The G Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Nuclear Estrogen Receptor Activity and Stimulates Novel Phosphoproteomic Signatures. 
  • The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. 
  • The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. 
  • The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. 
  • The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. 
  • The distal cytoplasmic domain of the erythropoietin receptor induces granulocytic differentiation in 32D cells. 
  • The genetic basis of a plant-insect coevolutionary key innovation. 
  • The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. 
  • The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. 
  • The role of N-cadherin/c-Jun/NDRG1 axis in the progression of prostate cancer. 
  • Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. 
  • Treating the biochemical recurrence of prostate cancer after definitive primary therapy. 
  • Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy. 
  • Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. 
  • Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. 
  • WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an autocrine manner to increase cancer cell migration. 
  • Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer. 
  • Whole-genome analysis informs breast cancer response to aromatase inhibition. 
• 

  Keywords of People

  • Mitchell-Olds, Thomas, Newman Ivey White Distinguished Professor of Biology, Biology
  • Starmer, Charles Franklin, Professor Emeritus of Computer Science, Computer Science